NYSEMKT: ARMP
Armata Pharmaceuticals Inc Stock

$1.68-0.16 (-8.7%)
Updated Mar 25, 2025
ARMP Price
$1.68
Fair Value Price
N/A
Market Cap
$60.79M
52 Week Low
$1.63
52 Week High
$4.25
P/E
-3.23x
P/B
-1.27x
P/S
12.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.17M
Earnings
-$18.92M
Gross Margin
100%
Operating Margin
-157.98%
Profit Margin
-365.6%
Debt to Equity
-2.8
Operating Cash Flow
-$38M
Beta
0.34
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A

ARMP Overview

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company is headquartered in Marina Del Rey, California and currently employs 30 full-time employees. The firm is focused on the discovery, development and commercialization of phage therapeutics. The firm is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The firm is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ARMP's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ARMP
Ranked
Unranked of 481

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ARMP news, forecast changes, insider trades & much more!

ARMP News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARMP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ARMP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ARMP is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ARMP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ARMP due diligence checks available for Premium users.

Valuation

ARMP price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-3.23x
Industry
-116.9x
Market
32.24x

ARMP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-1.27x
Industry
4.62x

ARMP's financial health

Profit margin

Revenue
$1.2M
Net Income
$2.6M
Profit Margin
210.5%
ARMP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ARMP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$86.4M
Liabilities
$134.5M
Debt to equity
-2.8
ARMP's short-term liabilities ($48.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARMP's long-term liabilities ($86.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARMP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ARMP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.9M
Investing
$77.0k
Financing
$0.0
ARMP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ARMP vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ARMP$60.79M-8.70%-3.23x-1.27x
IMRXF$60.65M-2.87%-0.83x1.47x
GANXD$60.48M-1.72%-2.07x6.79x
QNCXD$60.28M-2.14%-1.05x2.00x
GUTSF$60.17M-5.38%-0.76x2.12x

Armata Pharmaceuticals Stock FAQ

What is Armata Pharmaceuticals's quote symbol?

(NYSEMKT: ARMP) Armata Pharmaceuticals trades on the NYSEMKT under the ticker symbol ARMP. Armata Pharmaceuticals stock quotes can also be displayed as NYSEMKT: ARMP.

If you're new to stock investing, here's how to buy Armata Pharmaceuticals stock.

What is the 52 week high and low for Armata Pharmaceuticals (NYSEMKT: ARMP)?

(NYSEMKT: ARMP) Armata Pharmaceuticals's 52-week high was $4.25, and its 52-week low was $1.63. It is currently -60.47% from its 52-week high and 3.07% from its 52-week low.

How much is Armata Pharmaceuticals stock worth today?

(NYSEMKT: ARMP) Armata Pharmaceuticals currently has 36,183,067 outstanding shares. With Armata Pharmaceuticals stock trading at $1.68 per share, the total value of Armata Pharmaceuticals stock (market capitalization) is $60.79M.

Armata Pharmaceuticals stock was originally listed at a price of $183,750.00 in Dec 31, 1997. If you had invested in Armata Pharmaceuticals stock at $183,750.00, your return over the last 27 years would have been -100%, for an annualized return of -34.93% (not including any dividends or dividend reinvestments).

How much is Armata Pharmaceuticals's stock price per share?

(NYSEMKT: ARMP) Armata Pharmaceuticals stock price per share is $1.68 today (as of Mar 25, 2025).

What is Armata Pharmaceuticals's Market Cap?

(NYSEMKT: ARMP) Armata Pharmaceuticals's market cap is $60.79M, as of Mar 26, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Armata Pharmaceuticals's market cap is calculated by multiplying ARMP's current stock price of $1.68 by ARMP's total outstanding shares of 36,183,067.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.